Sean M. Healey & AMG Center for ALS
The Sean M. Healey & AMG Center at Mass General will launch the first platform trial for amyotrophic lateral sclerosis (ALS) to accelerate the development of effective and breakthrough treatments for people with ALS.
Read articlePharma Times writes about Oxford BioDynamics' role in testing a new ALS drug, with primary investigator James Berry, MD, MPH of Mass General.
Boston Globe coverage of the HEALEY ALS Platform Trial, which is starting with five promising new drugs and ambitious plans to accelerate the pace of discovery for ALS treatments.
Join our quest to discover life-saving therapies for individuals who are affected by ALS. The key to our success is our dedication to collaboration. At the Sean M. Healey and AMG Center for ALS at Mass General, we partner with the best clinician-scientists, our patients and friends like you to turn laboratory successes into promising therapies.
